Network NCC About Clinical Practice Guidelines. Accessed: Oct. 27, 2024. [Online]. Available: https://www.nccn.org/guidelines/guidelines-process/about-nccn-clinical-practice-guidelines

Meijers-Heijboer H et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations: The CHEK2-breast cancer consortium. Nat Genet 31(1). https://doi.org/10.1038/ng879

Breast Cancer Association Consortium (2021) Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women. N Engl J Med. https://doi.org/10.1056/NEJMoa1913948

Article  Google Scholar 

Hu C et al (2021) A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med 384(5). https://doi.org/10.1056/nejmoa2005936

Garmendia D, Weidner A, Venton L, Pal T (2024) Comparing Cancer Risk Management between Females with Truncating CHEK2 1100delC versus Missense CHEK2 I157T Variants, Genes (Basel)., vol. 15, no. 7, Jul

Kumpula TA et al (2023) Evaluating the role of CHEK2 p.(Asp438Tyr) allele in inherited breast cancer predisposition. Fam Cancer 22(3). https://doi.org/10.1007/s10689-023-00327-2

Network NCC NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 2.2023, National Comprehensive Cancer Network

Center NCC (2021) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic Version 1.2022. Aug

Muranen TA et al (2016) Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium. Breast Cancer Res 18(1). https://doi.org/10.1186/s13058-016-0758-5

Sutcliffe EG et al (2020) Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing. Cancer Genet 246–247. https://doi.org/10.1016/j.cancergen.2020.07.001

Network NCC NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian, Pancreatic and Prostate Version 2.2025, National Comprehensive Cancer Network

Hanson H et al (2023) Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Sci 25(10). https://doi.org/10.1016/j.gim.2023.100870

Mundt E et al (2023) Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants. Cancer Genet 278–279. https://doi.org/10.1016/j.cancergen.2023.10.002

Cybulski C et al (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75(6). https://doi.org/10.1086/426403

O. Online Mendelian Inheritance in Man and B. M. Johns Hopkins University, CHECKPOINT KINASE 2; CHEK2, Online Mendelian Inheritance in Man, OMIM®. Accessed: Jun. 01, 2024. [Online]. Available: World Wide Web URL: https://omim.org/

Anaclerio F et al (2023) Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis. Front Genet 14. https://doi.org/10.3389/fgene.2023.1060504

Network NCC NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric version 3.2024, National Comprehensive Cancer Network

Kilbride MK (2020) When variants are reclassified—the importance of personalized communication. Nat Med 26(1). https://doi.org/10.1038/s41591-019-0707-9

Makhnoon S, Davidson E, Shirts B, Arun B, Shete S (2023) Practices and Views of US Oncologists and Genetic Counselors Regarding Patient Recontact After Variant Reclassification: Results of a Nationwide Survey. JCO Precis Oncol 7 https://doi.org/10.1200/po.23.00079

Article  PubMed  PubMed Central  Google Scholar 

David KL et al (2019) Patient re-contact after revision of genomic test results: points to consider—a statement of the American College of Medical Genetics and Genomics (ACMG). Genet Sci 21(4). https://doi.org/10.1038/s41436-018-0391-z

Ivanov M et al (2022) Letter to the Editor: CHEK2 I157T - Pluto Among Numerous Low-Risk Genetic Factors Requiring Discharge From a Range of Pathogenic Variants? https://doi.org/10.6004/jnccn.2021.7103

Weis L, Bychkovsky B, Rodríguez AH, Barroso-Sousa R, Sandoval R (2025) CHEK2-related breast cancer: real-world challenges, Fam. Cancer, vol. 24, no. 23, Feb. https://doi.org/10.1007/s10689-025-00448-w

Reyes KG, Clark C, Gerhart M, Newson AJ, Ormond KE (2022) I wish that there was more info’: characterizing the uncertainty experienced by carriers of pathogenic ATM and/or CHEK2 variants. Fam Cancer 21(2). https://doi.org/10.1007/s10689-021-00251-3

Goodwin JS, Singh A, Reddy N, Riall TS, Kuo YF (2011) Overuse of screening colonoscopy in the medicare population. Arch Intern Med 171(15). https://doi.org/10.1001/archinternmed.2011.212

Predmore Z, Pannikottu J, Sharma R, Tung M, Nothelle S, Segal JB (2018) Factors Associated With the Overuse of Colorectal Cancer Screening: A Systematic Review. Am J Med Qual 33(5). https://doi.org/10.1177/1062860618764302

Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR (2017) Financial hardships experienced by cancer survivors: A systematic review. https://doi.org/10.1093/jnci/djw205

Brill JV (2020) Screening for cancer: The economic, medical, and psychosocial issues. Am J Managed Care 26. https://doi.org/10.37765/AJMC.2020.88534

Srivastava S et al (2019) Cancer overdiagnosis: a biological challenge and clinical dilemma. Nat Rev Cancer 19(6). https://doi.org/10.1038/s41568-019-0142-8

Jimbo M et al (2013) What is lacking in current decision aids on cancer screening? CA Cancer J Clin 63(3). https://doi.org/10.3322/caac.21180

Peterson EB et al (2016) Impact of provider-patient communication on cancer screening adherence: A systematic review. https://doi.org/10.1016/j.ypmed.2016.09.034

Samimi G et al (2020) Cancer Prevention in Primary Care: Perception of Importance, Recognition of Risk Factors and Prescribing Behaviors. Am J Med 133(6). https://doi.org/10.1016/j.amjmed.2019.11.017

Sepucha KR, Fowler FJ, Mulley AG (2004) Policy support for patient-centered care: The need for measurable improvements in decision quality. https://doi.org/10.1377/hlthaff.var.54

Rogen K, Ramczyk B, Bachinski T, Wham D, Schoenebeck AM, Mullane MP (2023) A Comprehensive Cancer Risk Management Clinic for Families With Hereditary Cancer Syndromes Outcomes After 6 Years. https://doi.org/10.3928/25731777-20230710-08

Knerr S et al (2023) Longitudinal adherence to breast cancer surveillance following cancer genetic testing in an integrated health care system. Breast Cancer Res Treat 201(3). https://doi.org/10.1007/s10549-023-07007-w

Woolf SH et al (2018) Engaging Patients in Decisions About Cancer Screening: Exploring the Decision Journey Through the Use of a Patient Portal. Am J Prev Med 54(2). https://doi.org/10.1016/j.amepre.2017.10.027

Lebrett MB et al (2022) Risk perception and disease knowledge in attendees of a community-based lung cancer screening programme. Lung Cancer 168. https://doi.org/10.1016/j.lungcan.2022.04.003

Tilburt JC et al (2011) Factors influencing cancer risk perception in high risk populations: A systematic review. Hered Cancer Clin Pract 9(1). https://doi.org/10.1186/1897-4287-9-2